Background: Resistance to erythropoiesis-stimulating agents (ESAs) has been observed in patients with chronic kidney disease (CKD) and it is associated with clinical outcomes. The presence of ESA resistance cannot always be explained by the known risk factors of the condition, suggesting that additional factors may be involved. We wanted to test the hypothesis that vitamin D insufficiency is associated with lower hemoglobin (Hb) and ESA resistance in patients on maintenance hemodialysis (HD). Methods: Data from patients receiving maintenance HD in a single dialysis center were extracted from the medical records in a retrospective chart review. Basic patient characteristics and laboratory data including Hb, serum albumin, intact parathyroid hormone and serum 25(OH)-cholecalciferol (25(OH)D3) levels were collected. ESA dose and Kt/V were extracted from the dialysis charts. Correlation analysis and multivariate linear regression analysis were used to reveal potential independent associations between clinical and laboratory parameters and ESA resistance. Results: Data from 142 patients were analyzed. Serum 25(OH)D3 concentration was significantly correlated with Hb (ρ = 0.186, p < 0.05) and also with ESA dose/Hb index (ρ = 0.230, p < 0.01). In multivariable regression analyses, serum 25(OH)D3 concentration remained significantly associated with both Hb and ESA dose/Hb index after controlling for potentially important confounders. Conclusion: Serum 25(OH)D3 concentration is independently associated with erythropoietin responsiveness in CKD patients on maintenance HD. If this association will be confirmed, treatment trials looking at the effect of vitamin D supplementation on anemia treatment in CKD patients may be warranted.

1.
Hsu CY, Bates DW, Kuperman GJ, Curhan GC: Relationship between hematocrit and renal function in men and women. Kidney Int 2001;59:725–731.
2.
Astor BC, Muntner P, Levin A, Eustace JA, Coresh J: Association of kidney function with anemia. Arch Intern Med 2002;162:1401–1408.
3.
Regidor DL, Kopple JD, Kovesdy CP, et al: Association between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 2006;17:1181–1191.
4.
Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE: The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 1996;28:53–61.
5.
Ishani A, Solid CA, Weinhandl ED, Gilbertson DT, Foley RN, Collins AJ: Nephrol Dial Transplant 2008;23:1682–1689.
6.
Molnar MZ, Czira M, Ambrus C, et al: Anemia is associated with mortality in kidney-transplanted patients – a prospective cohort study. Am J Transplant 2007;7:818–824.
7.
Bárány P, Müller HJ: Maintaining control over haemoglobin levels: optimizing the management of anaemia in chronic kidney disease. Nephrol Dial Transplant 2007;22(suppl 4):iv10–iv18.
8.
Collins AJ, Brenner RM, Ofman JJ, et al: Epoetin alfa use in patients with ESRD: an analysis of recent US prescribing patterns and hemoglobin outcomes. Am J Kidney Dis2005;46:481–488.
9.
Ebben JP, Gilbertson DT, Foley RN, Collins AJ: Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations. Clin J Am Soc Nephrol 2006;1:1205–1210.
10.
Kalantar-Zadeh K, Lee GH, Miller JE, et al: Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients. Am J Kidney Dis 2009;53:823–834.
11.
Richardson D: Clinical factors influencing sensitivity and response to epoetin. Nephrol Dial Transplant 2002;17(suppl 1):53–59.
12.
Smrzova J, Balla J, Bárány P: Inflammation and resistance to erythropoiesis-stimulating agents – what do we know and what needs to be clarified? Nephrol Dial Transplant 2005;20(suppl 8):viii2–viii7.
13.
Macdougall IC: Poor response to erythropoietin: practical guidelines on investigation and management. Nephrol Dial Transplant 1995;10:607–614.
14.
Van der Putten K, Braam B, Jie KE, Gaillard CA: Mechanisms of disease: erythropoietin resistance in patients with both heart and kidney failure. Nat Clin Pract Nephrol 2008;4:47–57.
15.
Johnson DW, Pollock CA, Macdougall IC: Erythropoiesis-stimulating agent hyporresponsiveness. Nephrology 2007;12:321–330.
16.
Rossert J, Gassmann-Mayer C, Frei D, McClellan W: Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients. Nephrol Dial Transplant 2007;22:794–800.
17.
Drüeke T: Hyporesponsiveness to recombinant human erythropoietin. Nephrol Dial Transplant 2001;16(suppl 7):25–28.
18.
Macdougall IC, Cooper AC: Hyporesponsiveness to erythropoietic therapy due to chronic inflammation. Eur J Clin Invest 2005;35(suppl 3):32–35.
19.
Kwack C, Balakrishnan VS: Managing erythropoietin hyporesponsiveness. Semin Dial 2006;19:146–151.
20.
Brancaccio D, Cozzolino M, Gallieni M: Hyperparathyroidism and anemia in uremic subjects: a combined therapeutic approach. J Am Soc Nephrol 2004;15:S21–S24.
21.
Kausz AT, Solid C, Pereira BJG, Collins AJ, St. Peter W: Intractable anemia among hemodialysis patients: a sign of suboptimal management or a marker of disease? Am J Kidney Dis 2005;45:136–147.
22.
Zhang Y, Thamer M, Stefanik K, Kaufman J, Cotter DJ: Epoetin requirement predict mortality in hemodialysis patients. Am J Kidney Dis 2004;44:866–876.
23.
Locatelli F, Conte F, Marcelli D: The impact of haematocrit levels and erythropoietin treatment on overall and cardiovascular mortality and morbidity-the experience of the Lombardy Dialysis Registry. Nephrol Dial Transplant 1998;13:1642–1644.
24.
Kilpatrick RD, Critchlow CW, Fishbane S, et al: Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clin J Am Soc Nephrol 2008;3:1077–1083.
25.
Zittermann A: Vitamin D in preventive medicine: are we ignoring the evidence? Br J Nutr 2003;89:552–572.
26.
Holick MF: Vitamin D for health and in chronic kidney disease. Semin Dial 2005;18:266–275.
27.
Wolf M, Shah A, Gutierrez O, et al: Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007;72:1004–1013.
28.
Holick MF, Lim R, Dighe AS: Case 3-2009: a 9-month-old boy with seizures. N Engl J Med 2009;360:398–407.
29.
Heaney RP: Vitamin D in health and disease. Clin J Am Soc Nephrol 2008;3:1535–1541.
30.
Aucella F, Scalzulli RP, Gatta G, Vigilante M, Carella AM, Stallone C: Calcitriol increases burst-forming unit – erythroid proliferation in chronic renal failure. Nephron Clin Pract 2003;95:c121–c127.
31.
Alon DB, Chaimovitz C, Dvilansky A, et al: Novel role of 1,25(OH)2D3 in induction of erythroid progenitor cell proliferation. Exp Hematol 2002;30:403–409.
32.
Ertürk S, Kutlay S, Karabulut HG, et al: The impact of vitamin D receptor genotype on the management of anemia in hemodialysis patients. Am J Kidney Dis 2002;40:816–823.
33.
Sezer S, Tutal L, Bilgic A, Ozdemir FN, Haberal M: Possible influence of vitamin D receptor gene polymorphisms on recombinant human erythropoietin requirements in dialysis patients. Transpl Proc 2007;39:40–44.
34.
Albitar S, Genin R, Fen-Chong M, Serveaux MO, Schohn D, Chuet C: High-dose alfacalcidol improves anaemia in patients on haemodialysis. Nephrol Dial Transplant 1997;12:514–518.
35.
Neves PL, Trivino J, Casaubon F, et al: Elderly patients on chronic hemodialysis with hyperparathyroidism: increase of hemoglobin level after intravenous calcitriol. Int Urol Nephrol 2006;38:175–177.
36.
Goicoechea M, Vazquez MI, Ruiz MA, Gomez-Campdera F, Perey-Garcia R, Valderrabano F: Intravenous calcitriol improves anaemia and reduces the need for erythropoietin in haemodialysis patients. Nephron 1998;78:23–27.
37.
Kendrick J, Targer G, Smits G, Chonchol M: 25-Hydroxyvitamin D deficiency and inflammation and their association with hemoglobin levels in chronic kidney disease. Am J Nephrol 2009;30:64–72.
38.
Patel NM, Gutiérrez OM, Andress DL, et al: Vitamin D deficiency and anemia in early chronic kidney disease. Kidney Int 2010;77:715–720.
39.
Fournier A, Fardellone P, Achard JM, et al: Importance of vitamin D repletion in uraemia. Nephrol Dial Transplant 1999;14:819–823.
40.
Deicher R, Hörl WH: Hormonal adjuvants for the treatment of renal anaemia. Eur J Clin Invest 2005;35(suppl 3):75–84.
41.
Haussler MR, Whitfield GK, Haussler CA, et al: The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res 1998;13:325–349.
42.
Holick MF: Vitamin D and sunlight: strategies for cancer prevention and other health benefits. Clin J Am Soc Nephrol 2008;3:1548–1554.
43.
Kovesdy CP, Kalantar-Zadeh: Vitamin D receptor activation and survival in chronic kidney disease. Kidney Int 2008;73:1355–1363.
44.
Cunningham J, Makin H: How important is vitamin D deficiency in uraemia? Nephrol Dial Transplant 1997;12:16–18.
45.
Cannata-Andía JB, Gómez Alonso C: Vitamin D deficiency: a neglected aspect of disturbed calcium metabolism in renal failure. Nephrol Dial Transplant 2002;17:1875–1878.
46.
Gómez-Alonso C, Naves-Díaz ML, Fernandez-Martin JL, Díaz-López JB, Fernandez-Coto MT, Cannata-Andia JB: Vitamin D status and secondary hyperparathyroidism: the importance of 25-hydroxyvitamin D cut-off levels. Kidney Int 2003;63:S44–S48.
47.
Mucsi I, Almási C, Deák GY, et al: Serum 25(OH)-vitamin D levels and bone metabolism in patients on maintenance hemodialysis. Clin Nephrol 2005;64:288–294.
48.
Scharla SH: Prevalence of subclinical vitamin D deficiency in different European countries. Osteoporos Int 1998;8(suppl 2):S7–S12.
49.
Ghazali A, Fardellone P, Pruna A, et al: Is low plasma 25(OH)-vitamin D a major risk factor for hyperparathyroidism and Looser’s zones independent of calcitriol? Kidney Int 1999;55:2169–2177.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.